Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-19-038133
Filing Date
2019-06-19
Accepted
2019-06-19 18:35:46
Documents
2
Period of Report
2019-06-19

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 9151
2 POA DOCUMENT poa.txt EX-24.3_861161 3710
  Complete submission text file 0001209191-19-038133.txt   14947
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 3 | Act: 34 | File No.: 001-38939 | Film No.: 19907147

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6400
OrbiMed Capital GP VI LLC (Reporting) CIK: 0001682115 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38939 | Film No.: 19907148

Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Issuer) CIK: 0001714798 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
SIC: 2836 Biological Products, (No Diagnostic Substances)